(Reuters) - AstraZeneca Plc's diabetes drug Onglyza appears to be associated with an increased rate of death, according to a review of data published by the U.S. Food and Drug Administration on Friday.
via Reuters: Health News Read More Here..
No comments:
Post a Comment